首页
患者中心
患者招募
关于我们
董事长致辞
公司简介
管理团队
创新与药物
研究领域
产品管线
医药新闻
公司新闻
医学进展
发表文章
联系我们
联系我们
中文
English
中文
English
首页
患者中心
患者招募
关于我们
董事长致辞
公司简介
管理团队
创新与药物
研究领域
产品管线
医药新闻
公司新闻
医学进展
发表文章
联系我们
联系我们
发表文章
公司新闻
医学进展
发表文章
A Novel Extended half-life factor VIII Fc fusion protein FRSW107 for severe hemophilia A: A multicentre, open-label, single-arm, phase 3 study and its open-label extension
An Open-label,Dose-Escalation, Multicenter Phase I Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics/pharmacodynamics(PK/PD)of Single Dose SS109 in Hemophilia A/B patients with Inhibitor
The in vitro and in vivo hemostatic efficacies of a novel FVIIIamimetic bispecific antibody, SS315, for the treatment of Hemophilia A.
Pharmacokinetics, Safety and Preliminary Efficacy of Multiple Doses of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) in Previously Treated Adult and Adolescent Subjects with Severe Hemophilia a: Results from an Open-
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of a PEGylated-Recombinant Human Coagulation Factor VIII-Fc Fusion Protein in Patients With Severe Hemophilia A
A Phase 1 Study to Evaluate the PK, Safety and Tolerability of a PEGylated-Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) with Extended Half-Life in Patients With Severe Hemophilia A
Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study
共7条
1